Learning objectives
To access imaging findings of growing teratoma syndrome (GTS), which is rare, benign complication of malignant ovarian germ cell tumour (GCT) following chemotherapy.
Key points •
Growing teratoma syndrome (GTS) is a complication of malignant germ cell tumours with benign pathology.
•
The imaging findings of GTS lesions were an increased fatty component within the mass or an entirely cystic lesion in the peritoneal cavity.
• Recognition of GTS is important for the determination of an optimal treatment strategy.
Background
In malignant germ cell tumour (GCT) patients, an enlargement or new development of tumour masses is sometimes detected, yet tumour marker levels decrease. This situation has been described as growing teratoma syndrome (GTS), since the increase of the tumour is composed of mature teratoma component. GTS is a rare metastatic complication that occurs in patients with malignant GCT following appropriate systemic chemotherapy. Three criteria are required for the diagnosis of GTS, as defined by Logothetis and colleagues: (a) Clinical or radiological enlargement of tumours during or after chemotherapy administered for non-seminomatous GCT, (b) Normalisation of previously elevated tumour markers (alpha fetoprotein [AFP] and/or human chorionic gonadotrophin [hCG] ) and (c) Absence of any immature component other than a mature teratoma at tumour resection. Although GTS is a well-known complication following nonseminomatous GCTs of the testis, with an incidence of around 1.9-7.6%, GTS occurs less commonly following ovarian GCT. The distinction between GTS and the recurrence of a malignant tumour is important because of the obvious differences in management. Whereas GTS may be managed by surgical resection, a recurred tumour warrants chemotherapy. However, GTS is frequently misdiagnosed as a recurrence because of a lack of awareness of the disease entity and imaging findings. Since the initial description of this entity in the ovary, reports in the radiology literature have been limited. This study describes computed tomography (CT) and magnetic resonance imaging (MRI) findings of GTS in five female patients.
Findings and procedure details
Radiologic findings of primary ovarian GCT and GTS are summarised in Table 1 and 2. In Cases 1 and 5, there were peritoneal seeding masses at the initial presentation of the ovarian immature teratomas. The primary ovarian tumours were seen as heterogeneous masses with a scant amount of fatty tissue. After resection with the macroscopic residual disease at the resection margin and adjuvant chemotherapy for the primary tumours, the follow-up CT revealed GTS lesions which manifested as gradually enlarging, poorlycircumscribed masses with a form of diffuse peritoneal seeding. In Case 1, the GTS lesions were mixed solid and cystic peritoneal masses, which had significantly larger amounts of fatty portions than the primary tumour. After the second operation, which was performed 5 months after the initial surgery, the patient was conservatively treated and there were regrowing peritoneal masses with a similar appearance to the GTS lesions. These were continually enlarging, which was observed on a follow-up CT. In Case 5, the GTS lesions were mixed solid and cystic peritoneal masses with multifocal fatty components, as seen on the CT and MRI. These lesions also revealed significantly larger fatty components than the primary tumour. After the second operation was performed, the tumours did not recur during two years of follow-up.
In Case 2, the patient only underwent a MRI as an initial imaging study and it showed bilateral solid and cystic ovarian masses without gross fat or calcification, which were pathologically confirmed as immature teratomas. After complete resection and adjuvant chemotherapy, the patient was followed-up for 7 years with physical examination and tumour marker analysis. A CT was performed 7 years after the initial surgery and revealed four well-circumscribed GTS lesions along the peritoneum. The lesions were predominantly cystic or solid and cystic masses with multifocal fatty components and calcifications, as seen on CT. The second operation was performed and the GTS lesions were completely resected. The patient was in remission 3 years after second operation.
In Case 3 and 4, the primary ovarian GCTs were pathologically endodermal sinus tumours which were accompanied by mature teratomas. The primary tumours were seen as mixed solid and cystic ovarian masses without gross fat or calcification. After complete resection and chemotherapy for the primary tumours, a follow-up CT showed GTS lesions in the ovaries of each patient. In Case 3, the CT revealed a GTS lesion that manifested as a gradually growing, well-circumscribed fatty mass in the left ovary. The second operation achieved complete resection and the patient had no evidence of recurrence after 6 years of follow-up. In Case 4, a purely cystic mass was identified on 1-year follow-up CT after the initial resection of the primary tumour and was confirmed to be a GTS lesion. A followup CT scan done 1 year after the second operation showed a newly developed fatty mass in the right ovary, which has not yet been pathologically confirmed.
In summary, the GTS lesions were demonstrated to be intraperitoneal masses in all patients: poorly-circumscribed diffuse peritoneal masses in 2 patients, well-circumscribed localised peritoneal masses in 1 and ovarian masses in 2. Two GTS lesions in the form of diffuse and poorly-circumscribed peritoneal masses were noted in patients who had peritoneal implants at the initial presentation of the malignant ovarian GCT. Upon comparison of the GTS lesions with the primary GCTs in regard to the composition of the tumours, imaging features which were more noticeable in the GTS lesions than in the primary tumour were fatty components in 3 patients, both a fatty component and calcification in 1 patient and a purely cystic lesion without a solid component in 1 patient.
18F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT scan was performed in four patients and the GTS lesions showed hyper-metabolism in two patients.
Images for this section: (Fig. 2) , at postoperative 2 months just before initiation of chemotherapy ( Fig. 3) and at 3 months after initiation of chemotherapy (Fig. 4) showed a growing mass (arrows in Fig. 3 and Fig. 4 ) with an increasing volume of fat (white arrowheads in Fig. 4 ) and calcification (black arrowheads in Fig. 3 and Fig. 4 ) in the rectouterine pouch (Fig. 7 ) and microscopic image (hematoxylin and eosin stain, x100) of the resected specimen (Fig. 8) showed a glistening whitish to yellowish mass which contained only mature elements without immature neuroepithelial tissue. (Fig. 7 ) and microscopic image (hematoxylin and eosin stain, x100) of the resected specimen (Fig. 8) showed a glistening whitish to yellowish mass which contained only mature elements without immature neuroepithelial tissue.
Fig. 9:
Figs. 9-11. A 37-year-old woman with growing teratoma syndrome following chemotherapy for an immature teratoma (case 2). Fig. 9 . Axial fat-suppressed T2-weighted image shows a heterogeneously solid and cystic mass (arrow) in the pelvic cavity that was pathologically confirmed as an immature teratoma of the right ovary. A 37-year-old woman with growing teratoma syndrome following chemotherapy for an immature teratoma (case 2). Axial CT performed at about 7 years after surgery shows newly developed, multiple well-circumscribed masses in the peritoneal cavity including a mixed solid and cystic mass in the perisplenic area (arrow on Fig. 10 ) and a predominantly cystic mass in the pelvic cavity (arrow on Fig. 11 ) with fat and calcification. These masses were confirmed as matured teratomas without any immature component.
Fig. 11:
Figs. 9-11. A 37-year-old woman with growing teratoma syndrome following chemotherapy for an immature teratoma (case 2). Axial CT performed at about 7 years after surgery shows newly developed, multiple well-circumscribed masses in the peritoneal cavity including a mixed solid and cystic mass in the perisplenic area (arrow on Fig. 10 ) and a predominantly cystic mass in the pelvic cavity (arrow on Fig. 11 ) with fat and calcification. These masses were confirmed as matured teratomas without any immature component. Fig. 16 . Axial CT performed 9 months after termination of chemotherapy shows a newly developed cystic mass (arrow) with a discernible wall in the pelvic cavity. This mass was confirmed to be a mature cystic teratoma of the right ovary. . Opposed-phase gradient-echo pulse sequence T1-weighted MR image (Fig. 17. ) and non-enhanced axial CT scan (Fig. 18) performed at initial presentation demonstrate a large heterogeneous mass with scant calcification (white arrowhead) and fat (black arrowheads) in the pelvic cavity which was pathologically confirmed as an immature teratoma of the left ovary.
Fig. 18:
Figs. 17-20. A 13-year-old girl with growing teratoma syndrome following chemotherapy for an immature teratoma (case 5). Opposed-phase gradient-echo pulse sequence T1-weighted MR image (Fig. 17. ) and non-enhanced axial CT scan (Fig. 18) performed at initial presentation demonstrate a large heterogeneous mass with scant calcification (white arrowhead) and fat (black arrowheads) in the pelvic cavity which was pathologically confirmed as an immature teratoma of the left ovary. (Fig. 2) , at postoperative 2 months just before initiation of chemotherapy ( Fig. 3) and at 3 months after initiation of chemotherapy (Fig. 4) showed a growing mass (arrows in Fig. 3 and Fig. 4 ) with an increasing volume of fat (white arrowheads in Fig. 4 ) and calcification (black arrowheads in Fig. 3 and Fig. 4 ) in the rectouterine pouch (Fig. 2) , at postoperative 2 months just before initiation of chemotherapy ( Fig. 3) and at 3 months after initiation of chemotherapy (Fig. 4) showed a growing mass (arrows in Fig. 3 and Fig. 4 ) with an increasing volume of fat (white arrowheads in Fig. 4 ) and calcification (black arrowheads in Fig. 3 and Fig. 4 ) in the rectouterine pouch Table 2 , Radiologic findings of growing teratoma syndrome in 5 patients 
